http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-015349-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 |
| filingDate | 2004-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21919fca0cb6b6112cc5407051b50768 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79cec613c3c94c3d4376704736b26415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f31656c8a45814bf5646196f9322d9dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f83fdd607193c24a2151d19ba6ca8c1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_534683b566711b79535c693927381403 |
| publicationDate | 2011-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-015349-B1 |
| titleOfInvention | SOLID, DIFFERENT, ORAL, PHARMACEUTICAL, DOSING, FORMING SAQUINAVIRMEZILATE AND METHOD FOR ITS MANUFACTURE |
| abstract | The invention describes a solid, single oral pharmaceutical dosage form of saquinavirmesylate containing a core and a core containing element selected from a film coating of a tablet, capsule or coating of an oval tablet, comprising from about 60 to about 80% of micronized saquinavirmesylate based on mesylate, from about 4 to about 8% of a pharmaceutically acceptable water-soluble binder, a pharmaceutically acceptable substance that provides disintegration, selected from the group comprising the sodium salt of cr carmellose and crospovidone, and a pharmaceutically acceptable carrier with a particle size of from about 30 to about 200 microns, where all percentages are based on the weight of the core of the pharmaceutical dosage form, where the core of the pharmaceutical dosage form includes a mixture of granulate and an additional component of granulate , in which the specified granulate includes micronized saquinavirmesylate, a binder, a carrier and a disintegrating agent, and an additional component of the granulate comprises a disintegrant, wherein the ratio of the disintegrant contained in the granulate, to the amount of the disintegrant contained in the additional component of the granulate is from about 3: 1 to about 1: 1. |
| priorityDate | 2003-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.